Best Biotech Companies To Own For 2014

[ August 24, 2013 | Author: admin | Weather: | Mood: normal]

The medical device industry can be a tricky field for those looking for investment advice. Between companies selling products in every category from drug-eluting stents to neuromodulation, where in the wide field of health care do you start? Fortunately, the ongoing earnings season has told us a few key trends every medical device investor can take advantage of. Here are three need-to-know points from the industry’s earnings season that your portfolio can’t afford to ignore.

This isn’t a biotech-style growth industry
First off, the medical device industry as a whole is facing some tough times. Pricing pressures, maturing markets, and a tough European business climate have all contributed to slowing or declining sales among the top names in the industry.

Take a look around the top device companies reporting this week, and you’ll see a picture of lackluster growth. Johnson & Johnson (NYSE: JNJ  ) , one of the biggest names in health care, saw double-digit growth from its medical device department, but only because of its $12 billion acquisition of orthopedics powerhouse Synthes last year. Fellow diversified medical firm Abbott Labs’ (NYSE: ABT  ) medical device sales fell more than 4% despite its dominant position in the stent industry. St. Jude Medical (NYSE: STJ  ) also saw sales decline 3% at a constant currency, even as the company managed to grow earnings by more than 5% by cutting costs.

Best Biotech Companies To Own For 2014: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headquartered in Fos t er City, California.

Advisors’ Opinion:

  • [By Dennis Slothower]

    Gilead Sciences is one of the top picks for some investors. While it may not be one of the best green stocks to invest in, the ROE and profit margin make it one to buy.

  • [By TheStreet Staff]

     Gilead Sciences (GILD) hits a snag that delays the filing, approval or launch of its all-oral Hepatitis C drug regimen. Investors also wake up to the realization that the commercial market for Hep C drugs is far smaller than expected. Gilead shares close in the red for the year. This is my Black Swan prediction for 2013.

  • [By CRWE]

    Gilead Sciences, Inc. (Nasdaq:GILD) reported that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada庐 (emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

Best Biotech Companies To Own For 2014: StemCells Inc (STEM.W)

StemCells, Inc. (StemCells), incorporated in August 1988, is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company

Comments are closed.